Latest Updates: August 2024
Data were updated in the following topics
As of 25 September 2023, a total of approximately 3,294 patients with relapsing multiple sclerosis (RMS) received ofatumumab in clinical trials including the ongoing open-label extension and there was approximately 112,482 patient-years post marketing experience1

References
1. Data on File. Periodic Safety Update Report (Cut-off date: 25 March 2023); Novartis Pharma AG.
**Last update included exposure, Ig levels, PML, malignancies, fatalities, COVID-19, pregnancy, pivotal trial, references and FAQ sections